{
    "2018-10-24": [
        [
            {
                "time": "",
                "original_text": "【广证恒生医药】健帆生物（300529）-业绩点评-灌流器肾病和肝病领域齐发力，2018年前三季度业绩50%超预期高速增长",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "灌流器",
                        "肾病",
                        "肝病",
                        "业绩点评",
                        "前三季度",
                        "50%增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}